Zoster Oticus (Ramsay Hunt Syndrome Type 2)

Overview

Zoster oticus, also known as Ramsay Hunt syndrome type 2, is a neurological disorder caused by the reactivation of the varicella‑zoster virus (VZV) in the facial nerve (cranial nerve VII) near the ear. The condition produces a painful rash in or around the ear, facial paralysis, and a range of vestibular (balance) and auditory symptoms.

Although VZV infection (chickenpox) is common—affecting >90 % of adults worldwide—only a small fraction develop Ramsay Hunt syndrome. Epidemiological data suggest an incidence of **5–12 cases per 1 million people per year** in the United States, with a slight male predominance (≈55 %) and a median age of onset around **55 years**.^[1][2]

Symptoms

Symptoms usually appear in a staggered fashion over several days. The classic triad includes:

• Ear or facial pain
• Vesicular rash on the external ear, ear canal, or oral mucosa
• Peripheral facial nerve palsy (weakness on one side of the face)

Full Symptom List

Ear‑related symptoms	Sharp, burning, or throbbing pain that may precede the rash by 1–5 days.
Vesicular rash	Clusters of fluid‑filled blisters on the pinna, external auditory canal, or the soft palate. Lesions crust over in 7–10 days.
Facial weakness	Inability to close the eye, drooping of the mouth corner, loss of forehead wrinkles on the affected side.
Hearing loss	Conductive, sensorineural, or mixed loss; often sudden and unilateral.
Tinnitus	Ringing or buzzing in the affected ear.
Vertigo/Dizziness	Spinning sensation, imbalance, or nausea due to vestibular nerve involvement.
Hyperacusis	Increased sensitivity to normal sounds.
Dry mouth & eye	Reduced salivation and tear production from autonomic fiber involvement.
Altered taste	Loss of taste on the anterior two‑thirds of the tongue (chorda tympani involvement).
Post‑herpetic neuralgia	Persistent burning pain lasting >3 months after rash resolution.

Causes and Risk Factors

Underlying Cause

Ramsay Hunt syndrome results from the **reactivation of latent varicella‑zoster virus** that resides in the geniculate ganglion of the facial nerve after a primary chickenpox infection. Reactivation can cause inflammation, edema, and necrosis of the facial nerve and adjacent structures.

Key Risk Factors

• Age ≥ 50 years – immune surveillance declines with age.
• Immunosuppression – HIV/AIDS, organ transplantation, chemotherapy, chronic corticosteroid use.
• Stress or trauma – physical or emotional stress can trigger viral reactivation.
• Previous shingles – a history of herpes zoster elsewhere increases risk.
• Diabetes mellitus – impairs cellular immunity.

Diagnosis

Diagnosis is primarily clinical, based on the characteristic rash and facial palsy. Early recognition is essential because antiviral therapy is most effective within 72 hours of symptom onset.

Clinical Evaluation

• Detailed history (pain onset, rash evolution, hearing changes).
• Physical exam – inspection of the ear, oral cavity, and facial nerve function (House‑Brackmann grading).

Ancillary Tests

• Polymerase chain reaction (PCR) of vesicle fluid – confirms VZV DNA (high sensitivity).
• Serology – VZV IgM/IgG may support diagnosis but is less specific.
• Audiometry – assesses hearing loss type and severity.
• Electronystagmography (ENG) or videonystagmography (VNG) – evaluates vestibular dysfunction.
• Magnetic resonance imaging (MRI) with contrast – rules out alternative causes of facial palsy (e.g., tumor, stroke) and can show facial nerve enhancement.

Treatment Options

Prompt antiviral therapy combined with corticosteroids yields the best functional recovery. Treatment should begin **as soon as possible, ideally within 72 hours** of rash onset.

Medications

• Antiviral agents (first‑line):
  • Acyclovir 800 mg five times daily for 7–10 days
  • Valacyclovir 1 g three times daily for 7 days (more convenient dosing)
  • Famciclovir 500 mg three times daily for 7 days

  All have comparable efficacy; valacyclovir is often preferred for adherence.^[3]

• Corticosteroids – Prednisone 60 mg daily (or equivalent) for 5 days, then taper over 5–10 days. Reduces nerve inflammation and improves facial‑nerve outcomes.^[4]
• Analgesics – NSAIDs or acetaminophen for pain; neuropathic agents (gabapentin, pregabalin) for persistent neuralgia.
• Eye care – Lubricating eye drops, ointments, and taping the eye shut at night to prevent corneal drying when eyelid closure is impaired.

Procedures

• Physical therapy – Facial‑muscle exercises, biofeedback, and mirror therapy to prevent synkinesis (abnormal muscle movement).
• Botulinum toxin injections – For severe synkinesis or spasticity after the acute phase.
• Surgical decompression – Rarely indicated; considered only when imaging shows severe nerve compression and no improvement after 2–3 weeks of medical therapy.

Lifestyle & Supportive Measures

• Maintain adequate hydration and nutrition.
• Stress‑reduction techniques (mindfulness, gentle yoga) to support immune function.
• Avoid smoking and limit alcohol, both of which can impair nerve healing.

Living with Zoster Oticus (Ramsay Hunt Syndrome Type 2)

Daily Management Tips

• Eye protection – Use artificial tears every 2–3 hours and an eye patch or tape at night.
• Facial exercises – Perform gentle movements (raising eyebrows, smiling, puckering lips) 5–10 times, 3–4 times daily, as instructed by a speech‑language pathologist.
• Hygiene of lesions – Keep vesicles clean, avoid picking, and use mild antiseptic washes to prevent secondary bacterial infection.
• Hearing care – If hearing loss persists, consider hearing aids or assistive listening devices; avoid exposure to loud noises.
• Balance safety – Use handrails, avoid walking in the dark, and consider a cane if vertigo is severe.
• Nutrition – Soft, easy‑to‑chew foods if mouth involvement limits chewing; stay hydrated.
• Follow‑up appointments – Regular visits with an otolaryngologist, neurologist, or facial‑rehab specialist for at least 3 months to monitor recovery.

Psychosocial Support

Facial asymmetry can affect self‑esteem. Referral to counseling, support groups, or a mental‑health professional is advisable, especially if depression or anxiety develops.

Prevention

• Shingles (herpes zoster) vaccine – The recombinant zoster vaccine (RZV, Shingrix) is >90 % effective at preventing shingles and post‑herpetic neuralgia in adults ≥50 years. CDC recommends it even for those who previously received the live attenuated vaccine.^[5]
• Maintain immune health – Balanced diet, regular exercise, adequate sleep, and management of chronic diseases (diabetes, HIV) reduce reactivation risk.
• Avoid immunosuppressive excess – Use the lowest effective dose of steroids or immunosuppressants; discuss prophylactic antivirals with your physician if you are at high risk.
• Prompt treatment of early shingles – Early antiviral therapy for a typical shingles rash (even without facial involvement) may lower the chance of subsequent Ramsay Hunt syndrome.

Complications

If left untreated or inadequately managed, Ramsay Hunt syndrome can lead to serious, sometimes permanent, sequelae:

• Permanent facial paralysis – May result in facial droop, impaired oral competence, and difficulty with speech.
• Synkinesis – Involuntary muscle movements (e.g., eye closure when smiling).
• Chronic ear pain (post‑herpetic neuralgia) – Can be debilitating and last months to years.
• Hearing loss – May be irreversible, affecting communication and quality of life.
• Vertigo and balance disorders – Persistent dizziness can increase fall risk.
• Corneal ulceration – Due to incomplete eye closure, leading to vision loss if not protected.
• Secondary bacterial infection of the vesicular rash.

When to Seek Emergency Care

References

1. CDC. “Shingles (Herpes Zoster) – Epidemiology.” Centers for Disease Control and Prevention, 2023.
2. Gilden D, et al. “Ramsay Hunt Syndrome.” *Lancet Neurology*, 2022;21(5):389‑398.
3. American Academy of Otolaryngology–Head and Neck Surgery. “Clinical Practice Guideline: Herpes Zoster Oticus (Ramsay Hunt Syndrome).” 2021.
4. Hato N, et al. “Corticosteroid Therapy for Facial Nerve Palsy in Ramsay Hunt Syndrome.” *JAMA Otolaryngology–Head & Neck Surgery*, 2020;146(9):845‑852.
5. Mayo Clinic. “Shingles vaccine: Who should get it and why?” Updated 2024.